NORCROSS, Ga.--(BUSINESS WIRE)--Auriga Laboratories, Inc. (OTCBB:ARGA), a specialty pharmaceutical company driving high-growth revenues through acquisition of valuable brand portfolios and innovative drug development programs, today announced the filing of a new provisional patent application for a novel expectorant treatment option for inclusion in several of the Company’s proprietary prescription drug products as well as strategic new indications.
